{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["30(7)"],"submitter":["Leone F"],"funding":["Servier Italia"],"pubmed_abstract":["<h4>Background</h4>Trifluridine/tipiracil (FTD/TPI), an oral fluoropyrimidine (FP) from the class of antimetabolites, approved for refractory metastatic colorectal cancer, is thought, to have no cardiac toxicity. The aim of this observational, prospective, multicenter study was to identify the incidence of cardiotoxicity of FTD/TPI; secondary objectives were to evaluate whether patients with previous heart diseases or cardiovascular risk factors, who were treated with FTD/TPI, were more susceptible to cardiotoxicity.<h4>Materials and methods</h4>Patients received FTD/TPI according to clinical practice and provided informed consent to participate in this prospective study. Any symptoms that occurred during the treatment were reported by patients using a daily questionnaire (patient-reported"],"journal":["The oncologist"],"pagination":["oyaf178"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12259526"],"repository":["biostudies-literature"],"pubmed_title":["Cartoon: multicenter prospective observational study of Cardiovascular Toxicity of Trifluridine/Tipiracil in metastatic colorectal cancer."],"pmcid":["PMC12259526"],"pubmed_authors":["Fiamma V","Nicoli E","Bertola B","Salerno F","Nepote A","Tober N","Crivelli F","Paris MK","Laface R","Parlagreco E","Traverso ES","Leone F","Sperti E","Bonessio E","Giuli A","Forti LG","Brizzi MP","Montagnani F"],"additional_accession":[]},"is_claimable":false,"name":"Cartoon: multicenter prospective observational study of Cardiovascular Toxicity of Trifluridine/Tipiracil in metastatic colorectal cancer.","description":"<h4>Background</h4>Trifluridine/tipiracil (FTD/TPI), an oral fluoropyrimidine (FP) from the class of antimetabolites, approved for refractory metastatic colorectal cancer, is thought, to have no cardiac toxicity. The aim of this observational, prospective, multicenter study was to identify the incidence of cardiotoxicity of FTD/TPI; secondary objectives were to evaluate whether patients with previous heart diseases or cardiovascular risk factors, who were treated with FTD/TPI, were more susceptible to cardiotoxicity.<h4>Materials and methods</h4>Patients received FTD/TPI according to clinical practice and provided informed consent to participate in this prospective study. Any symptoms that occurred during the treatment were reported by patients using a daily questionnaire (patient-reported","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-03-31T10:51:07.111Z","creation":"2025-08-28T03:05:44.447Z"},"accession":"S-EPMC12259526","cross_references":{"pubmed":["40660676"],"doi":["10.1093/oncolo/oyaf178"]}}